INTRODUCTION {#s1}
============

Amyotrophic lateral sclerosis (ALS) is an adult-onset idiopathic fatal neurodegenerative disease caused by highly selective loss of motor neurons ([@DDP498C1]). The main clinical features are insidious onset of upper and lower motor neuron degeneration and relatively linear progression over time. The main neuropathological features are loss of motor neurons. The age at onset is usually over 25 years and incidence increases slightly with age. The overall incidence of ALS is 2--3 per 100 000 and the prevalence is 6--10 per 100 000. Ninety to 95% of cases are sporadic (SALS) and 5--10% of cases are familial (FALS), for which ∼30% of the mutations have been identified to date. There are no effective treatments and death occurs in 90% of patients within 3--5 years. The mechanisms for the highly selective degeneration are unknown ([@DDP498C2]) and it is increasingly thought that non-neuronal cells are involved in the process ([@DDP498C3],[@DDP498C4]). It is now recognized that close associations between ALS and frontotemporal lobar dementia with ubiquitin and TDP-43 positive immunoreactivity exist at the clinical, pathological, and molecular levels ([@DDP498C5]).

Alternative exon splicing is now believed to be one of the major factors determining the complexity and functionality of the eukaryotic genome ([@DDP498C6]--[@DDP498C8]). It is one of the main mechanisms of gene and cell regulation, modulates the properties of encoded proteins by regulating expression and adding and deleting functional domains and likely involves most genes. The control of exon splicing involves regulatory proteins binding to a variety of sites on transcripts such as exon splicing enhancers that bind SR proteins, polypyrimidine tracts, and splice motifs. The primary mediator of splicing is the spliceosome, composed of over 100 splicing factors including proteins, RNA and small nuclear ribonucleoproteins, which associate with pre-mRNA to mediate intron excision and exon ligation ([@DDP498C9]). Abnormal splicing can result in disease and the list of diseases attributed to this continues to grow ([@DDP498C10]). Appreciation of the significance of exon splicing in the genome has grown recently due to better analytic techniques ([@DDP498C11]) and is now entering an even more rapid growth phase with technology to perform deep sequencing ([@DDP498C12]).

There is increasing evidence that implicates abnormalities of RNA processing and exon splicing in ALS pathogenesis ([@DDP498C13]). TDP-43, a protein that has known functions in RNA processing and regulation of exon splicing, mislocalizes from the nucleus to the cytoplasm in SALS, suggesting its nuclear pre-mRNA functions are fundamentally compromised ([@DDP498C14]--[@DDP498C16]). Mutations in the TARDBP gene encoding the TDP-43 protein are found in both FALS and SALS, indicating its role can be primary ([@DDP498C17]--[@DDP498C19]). There is strong evidence that the toxic property resides in the C-terminal fragments, an architecture that would likely compromise nuclear functions, including exon splicing. Recently, the FUS/TLS gene has been identified in FALS by virtue of its function in RNA processing ([@DDP498C20],[@DDP498C21]). Among the other genes identified to date in ALS as well other motor neuron degenerative disorders, there is over-representation of genes encoding proteins that are involved in RNA processing; these include: SETX, SMN, GARS, ATXN7, IGHMBP2 and ANG ([@DDP498C22]). A newly reported association has been identified between ALS and variants of a component of RNA polymerase II, elongator protein 3 ([@DDP498C23]). And spinal muscular atrophy (SMA), the most common motor neuron disease in childhood, is caused by homozygous loss of the SMN1 gene, which plays key roles in exon splicing ([@DDP498C24]).

Motor phenotypes of ALS indicate that underlying motor neuron degeneration is a focal process that progresses contiguously along neuronal anatomy ([@DDP498C25]). Neuropathological stages can be defined in relation to the site of onset, advanced in the region of onset and progressively less radially away ([@DDP498C26]). This creates opportunity for functional genomics analysis, as genomic signals can be isolated from regions in early to intermediate stages of degeneration and profiled using newly available laser and microchip technologies ([@DDP498C27],[@DDP498C28]). To pursue this, we created a tissue repository specifically for simultaneous genomic and structural studies, used histopathology to identify suitable neuron-rich regions, validated RNA quality and profiled exon and gene expression in motor neurons and its anterior horn microenvironment. Using powerful bioinformatics approaches, we identified biological signals in motor neuron enriched mRNA pools that appear to be perturbed in SALS, the strongest of which is abnormal exon splicing, especially in cell-matrix adhesion genes. The pathogenesis of SALS remains elusive and mainly pursued by way of laboratory models of genetic disease---our findings identify important new aspects directly in human sporadic disease.

RESULTS {#s2}
=======

Special processing of CNS coupled with laser capture microdissection permits collection and selective enrichment of relevant cellular compartments for genomic analysis {#s2a}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Major challenges facing genomic analysis of human degenerative disorders of the CNS are precise localization and isolation of the degenerating compartment and the proper acquisition of materials. As SALS disease typically exhibits a focal onset and subsequent spread ([@DDP498C25],[@DDP498C26]), patients whose disease began in bulbar and arm regions have caudally advancing disease and often have lumbar regions in relatively early stages of degeneration at the time of death. To exploit this, we developed an on-call autopsy system and rapidly harvested their nervous systems, usually completed within 6 h of death, and specifically processed them for downstream genomic and structural studies. We used histopathology to confirm that the lumbar regions distal to the site of onset had early or intermediate stage of disease pathology with abundant residual motor neurons and that they contained TDP-43 cytoplasmic deposits characteristic of SALS. Based upon this analysis and upon analysis of RNA quality as discussed below, we then chose nervous systems from the frozen inventory and collected from them motor neurons by laser capture microdissection in SALS (*n* = 12) and controls (*n* = 10) (Table [1](#DDP498TB1){ref-type="table"} and Fig. [1](#DDP498F1){ref-type="fig"}A). After we had completed collection of motor neurons by microdissection, we collected the remaining anterior horn region to create a second sample set, reasoning that this might be important for understanding disease pathogenesis given the strong evidence for non-autonomous degeneration in ALS ([@DDP498C3],[@DDP498C4]). For standardization, we studied lumbar regions in all cases, disease and control.

![Laser capture microdissection (LCM) permits collection of high quality RNA from SALS motor neurons. (**A**): (A1) This is a low-power transverse view of SALS lumbar spinal cord stained with H&E before LCM. The rectangle indicates the anterior horn. Note the relative abundance of residual lumbar motor neurons (purple spots) in this nervous system where disease onset was in arm and respiratory muscles. (A2) Same, after LCM---the small white blanks are where motor neurons were microdissected. Note the specificity that is achieved within the complex cytoarchitecture of the spinal cord. (A3) This is a mid-power view of motor neurons captured and adhering to a thermoplastic polymer film on an LCM cap. The cap fits into a microtube for RNA isolation. \[Scale bars are 1 mm in (A1) and (A2) and 100 µm in (A3)\]. (B) These are electropherograms (left side of each panel) and digital gels (right side of each panel) generated by digital micro-electrophoresis that is used to assess RNA quality. The column on the left (B1, B3 and B5) is from a SALS nervous system and the column on the right (B2, B4 and B6) is from a SOD1 G93A ALS1 transgenic mouse for comparison. The top row (B1 and B2) shows total RNA before processing by laser capture microdissection (LCM). The middle row (B3 and B4) shows total RNA of motor neurons after isolation by LCM. The bottom row (B5 and B6) shows messenger RNA from the laser captured motor neurons after amplification. The similarities in these tracings illustrate the high quality of RNAs generated from SALS patient materials.](ddp49801){#DDP498F1}

###### 

Demographic details

  Primary diagnosis   CNS ID number   Age   Gender   Site of onset   Disease course (years)   PMI (h)
  ------------------- --------------- ----- -------- --------------- ------------------------ ---------
  SALS                14              73    Female   Bulbar          1.5                      6
  SALS                16              61    Male     Arm             2.5                      3.5
  SALS                17              55    Male     Arm             2                        3
  SALS                18              80    Female   Bulbar          2                        4
  SALS                27              74    Male     Bulbar          3.25                     4
  SALS                33              54    Male     Arm             6.5                      5
  SALS                34              81    Female   Bulbar          1                        3.5
  SALS                35              74    Female   Bulbar          5.75                     5
  SALS                60              58    Female   Bulbar          3                        3
  SALS                63              68    Male     Arm             2.5                      5
  SALS                64              47    Male     Arm             3                        6.5
  SALS                68              72    Female   Leg             1.5                      4
  Control             10              78    Male     NA              NA                       2.5
  Control             19              80    Female   NA              NA                       2.5
  Control             26              49    Male     NA              NA                       4
  Control             39              77    Male     NA              NA                       2
  Control             42              61    Male     NA              NA                       6
  Control             44              80    Female   NA              NA                       5
  Control             55              71    Male     NA              NA                       13
  Control             59              73    Male     NA              NA                       8
  Control             65              82    Male     NA              NA                       4
  Control             67              77    Male     NA              NA                       4

RNA and microarray quality are high {#s2b}
-----------------------------------

The success of genomic profiling depends upon both RNA and microarray quality. To ensure RNA quality, we used digital micro-electrophoresis and performed extensive validation of RNA quality ([Supplementary Material S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). We found that our human RNA quality was high, RNA quality was sufficiently preserved through the steps of microdissection, and mRNA signals amplified to yield quantities and qualities necessary for microarray analysis (Fig. [1](#DDP498F1){ref-type="fig"}B). When RNA was optimal, we proceeded to label it, hybridize it to exon arrays, and process the arrays to CEL files. To ensure microarray quality, we examined CEL files in multiple ways (see Materials and Methods) and we found they were uniformly high ([Supplementary Material S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). We always processed equal numbers of SALS and controls together to minimize batch effects and upon completion of the studies, we measured batch effects and they were minimal (data not shown), indicating evenness of acquired data between disease and control. We compared both RNA and microarray quality with our analogous experiments in ALS1 G93A transgenic mice using 3′ gene expression arrays, which were performed under ideal laboratory-controlled conditions, and found they were comparable (RNA quality is shown in Figure [1](#DDP498F1){ref-type="fig"}B and CEL file data are not shown). Thus, we were reassured of the high quality and reliability of the signals we acquired with our approach.

Genomic analysis identifies differentially expressed gene signals in the motor neuron enriched mRNA pool {#s2c}
--------------------------------------------------------------------------------------------------------

We next looked at differential gene expression. One of the main challenges of doing this is ascertaining significance when there are multiple tests and uncertain levels of noise. To determine noise levels in our data, we created sham test groups by permuting CEL file test categories and computing differential gene expression 10 times and then compared differential gene expression in our true data with the sham data (see Materials and Methods). In the motor neuron enriched mRNA pool, we found robust differential expression and readily definable noise levels: we estimate a data-specific 5% noise threshold of *P*≈ 10^−3^ and at this level of significance, there are 148 differentially expressed genes in the true data set and an average of six genes (range 2--12) in the permuted data sets (Fig. [2](#DDP498F2){ref-type="fig"}A, Table [2](#DDP498TB2){ref-type="table"} and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). Most of the differentially expressed genes are up-regulated rather than down-regulated---for a fold change ≥1.5, 71 genes are up-regulated and 14 genes are down-regulated---suggesting increasing rather than decreasing molecular activity in the motor neuron enriched mRNA pool.

![Microarray analysis robustly identifies disease-associated signals in the SALS motor neuron enriched mRNA pool. (**A**) This graph shows the cumulative numbers of differentially expressed genes as a function of *P*-values. In this and in the other graphs, the solid line (arrow) shows the true comparison between SALS and control and the dashed lines (arrowhead) show sham comparisons of randomly permuted groups and indicate the noise levels in the data. Highly distinct differential gene expression is identified. (**B**) This graph shows the cumulative numbers of aberrantly spliced genes as a function of *P*-values. Note not only that significant aberrant gene splicing is identified, but also that the degree of abnormality is greater than seen with differential gene expression. (**C**) This graph shows cumulative numbers of Gene Ontology gene sets that enrich the differentially expressed genes identified in (A) as a function of *P*-value. There is no apparent biological enrichment of the differentially expressed genes. (**D**) This graph shows cumulative numbers of Gene Ontology gene sets that enrich the aberrantly spliced genes identified in (C) as a function of *P*-value. By comparison to differential gene expression, the aberrantly spliced genes are robustly enriched biologically. (**E**) Venn diagram comparing differentially expressed and aberrantly spliced genes in the SALS motor neuron enriched RNA pools. Note that the two cohorts of genes are distinctive and have only slight overlap.](ddp49802){#DDP498F2}

###### 

Top 25 aberrantly spliced and top 25 differentially expressed genes

  Gene symbol   Gene name                                                             RefSeq         Alt. splice *P*-value   Differential expression *P*-value   Fold-change (A versus C)   \# Markers (exons)
  ------------- --------------------------------------------------------------------- -------------- ----------------------- ----------------------------------- -------------------------- --------------------
  ABCA8         ATP-binding cassette, sub-family A (ABC1), member 8                   NM_007168      2.84E--17               0.0147702                           2.07853                    37
  ACADVL        Acyl-Coenzyme A dehydrogenase, very long chain                        NM_000018      0.07572                 9.62E-05                            −1.36709                   20
  AGTRL1        Angiotensin II receptor-like 1                                        NM_005161      0.00280309              0.000100449                         2.80667                    6
  AQP4          Aquaporin 4                                                           NM_001650      1.35E-27                1.21E−06                            3.17926                    13
  ASPA          Aspartoacylase (Canavan disease)                                      NM_000049      0.199691                0.000120487                         2.94572                    6
  C1orf198      Chromosome 1 open reading frame 198                                   AK096166       2.66E−16                0.00111187                          1.7294                     17
  C21orf33      Chromosome 21 open reading frame 33                                   NM_004649      0.0218155               0.00010392                          −1.30992                   10
  C3            Complement component 3                                                NM_000064      1.89E−23                0.00107972                          2.39112                    43
  C4A           Complement component 4A (Rodgers blood group)                         NM_007293      1.88E−31                0.000487554                         2.3395                     48
  CENTD1        Centaurin, delta 1                                                    NM_015230      9.18E−08                8.68E−05                            1.86511                    37
  COG5          Component of oligomeric golgi complex 5                               NM_006348      1.79E−05                0.000102532                         1.63965                    28
  COL1A2        Collagen, type I, alpha 2                                             NM_000089      2.02E−24                0.0319974                           1.44001                    47
  COL6A3        ollagen, type VI, Calpha 3                                            NM_004369      3.34E−20                0.0945555                           1.36456                    45
  CPVL          Carboxypeptidase, vitellogenic-like                                   NM_019029      3.89E−11                6.99E−06                            2.06165                    17
  CXCL16        Chemokine (C-X-C motif) ligand 16                                     NM_022059      0.00011424              2.01E−05                            1.99739                    10
  DST           Dystonin                                                              NM_183380      9.73E−24                0.323111                            1.0925                     125
  EDNRB         Endothelin receptor type B                                            NM_000115      2.64E−19                1.64E−05                            3.01733                    17
  ELAVL3        ELAV (embryonic lethal, abnormal vision, Drosophila)-like             NM_032281      1.12E−05                0.000109817                         −2.14778                   18
  EXOSC6        Exosome component 6                                                   NM_058219      0.804989                0.000105887                         −1.21483                   7
  FAM46C        Family with sequence similarity 46, member C                          NM_017709      6.43E−08                0.000117789                         2.4746                     6
  FLJ21963      FLJ21963 protein                                                      NM_024560      2.64E−12                2.35E−05                            3.01776                    17
  FLJ44874      FLJ44874 protein                                                      AK126822       0.597731                1.44E−07                            −1.46746                   3
  FLNC          Filamin C, gamma (actin-binding protein 280)                          NM_001458      2.80E−16                0.289023                            1.0877                     48
  FN1           Fibronectin 1                                                         NM_212482      2.24E−21                0.0133788                           2.50828                    63
  HIF3A         Hypoxia inducible factor 3, alpha subunit                             NM_022462      6.33E−16                0.0968477                           1.24509                    27
  HLA-B         Major histocompatibility complex, class I, B                          NM_005514      0.011742                0.000145132                         2.07808                    3
  HLA-DMB       Major histocompatibility complex, class II, DM beta                   NM_002118      0.00334092              0.000122339                         2.64162                    3
  HLA-DRA       Major histocompatibility complex, class II, DR alpha                  NM_019111      0.0176529               9.96E−06                            3.75813                    9
  INPP5D        Inositol polyphosphate-5-phosphatase, 145 kDa                         NM_005541      2.28E−15                0.00485491                          1.54023                    25
  KIAA0644      KIAA0644 gene product                                                 NM_014817      5.30E−18                0.0764209                           1.16279                    15
  KRT73         Keratin 73                                                            NM_175068      0.156092                6.78E−05                            −1.35392                   9
  LRP1          Low-density lipoprotein-related protein 1 (alpha-2-macroglo           NM_002332      2.68E−19                0.0219457                           1.28675                    105
  MACF1         Microtubule-actin cross-linking factor 1                              NM_012090      7.85E−22                0.00408213                          1.24486                    115
  MYBPC1        Myosin binding protein C, slow type                                   NM_002465      1.90E−21                0.00967833                          1.31138                    31
  OR2W3         Olfactory receptor, family 2, subfamily W, member 3                   NM_001001957   0.602669                0.000100305                         −1.45266                   13
  OR5AS1        Olfactory receptor, family 5, subfamily AS, member 1                  NM_001001921   0.548751                0.000141626                         −1.3982                    3
  PADI2         Peptidyl arginine deiminase, type II                                  NM_007365      9.72E−14                0.000114651                         1.6916                     18
  PARP9         Poly (ADP-ribose) polymerase family, member 9                         NM_031458      0.606104                2.15E−05                            3.48026                    3
  PCDHGC5       Protocadherin gamma subfamily C, 5                                    NM_018929      2.24E−21                0.00182203                          1.23154                    100
  PYGM          Phosphorylase, glycogen; muscle (McArdle syndrome, glycogen           NM_005609      7.14E−19                0.000661684                         1.64136                    20
  SEMA5B        Sema domain, seven thrombospondin Repeats (type 1 and                 NM_001031702   6.12E−25                0.746505                            1.02067                    31
  SF1           Splicing factor 1                                                     NM_004630      3.25E−18                0.0117229                           1.26463                    32
  SLC1A3        Solute carrier family 1 (glial high affinity glutamate transporter)   NM_004172      3.81E−05                0.000106293                         2.50395                    15
  SLC35A4       Solute carrier family 35, member A4                                   NM_080670      0.793629                7.95E−05                            −1.49356                   8
  SLC4A4        Solute carrier family 4, sodium bicarbonate co-transporter            NM_001098484   1.64E−16                0.000145173                         2.17261                    31
  TJP2          Tight junction protein 2 (zona occludens 2)                           NM_004817      9.14E−16                0.000452437                         2.01894                    31
  TRBV19        T-cell receptor beta variable 19                                      BC073930       1.48E−15                0.695085                            1.02684                    30
  UTRN          Utrophin                                                              NM_007124      1.56E−20                0.00473928                          1.78074                    74

Exon splicing is significantly aberrant in the motor neuron enriched mRNA pool and is distinct from and more pronounced than differential gene expression {#s2d}
---------------------------------------------------------------------------------------------------------------------------------------------------------

We next looked at exon splicing. To determine aberrant exon splicing, we used an ANOVA-based analysis that generates *P*-values indicating the probability of aberrant splicing occurring in a particular gene. The ANOVA-based analysis separates out many variables, most importantly overall gene expression levels. As with differential gene expression, one of the main challenges is ascertaining significance with multiple tests and uncertain levels of noise and we employed the same strategy of permutation analysis that we used in analyzing differential gene expression. In the motor neuron enriched mRNA pool, we again found robust signals and readily definable noise levels: we estimate a data-specific 5% noise threshold of *P*≈10^−5^ and at this level of significance, there are 411 aberrantly spliced genes in the true data set and an average of 21 genes (range 5--51) in the permuted data sets (Fig. [2](#DDP498F2){ref-type="fig"}B, Table [2](#DDP498TB2){ref-type="table"} and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). Comparing aberrantly spliced genes to differentially expressed genes, we see a nearly 3-fold greater number (411 versus 148) using our data-specific noise levels to define the respective cohorts. Analysis of these cohorts indicates only 29 genes overlap---7% of the 411 aberrantly spliced genes and 21% of the 148 differentially expressed genes (Fig. [2](#DDP498F2){ref-type="fig"}E)---thus showing that the cohorts of genes are distinct from each other. The greater numbers of aberrantly spliced genes than differentially expressed genes cannot be attributed to the greater degree of multiple testing since this and other methods of analysis we used correct for this. As with the differential gene expression, most of the aberrantly spliced genes were up-regulated rather than down-regulated. To examine the architecture of aberrant splicing in these genes, we classified splicing abnormalities in the top 100 genes and found that 56% had changes in internal exons, 51% in 5′ regions, 36% in 3′ regions and 42% in multiple locations (both internal and terminal) (data not shown).

The aberrantly spliced genes but not the differentially expressed genes in the motor neuron enriched mRNA pool are biologically enriched {#s2e}
----------------------------------------------------------------------------------------------------------------------------------------

One of the main challenges of microarray analysis is ascertaining biological importance of identified genes---statistical significance does not equate to biological significance. Multiple approaches have been designed to meet these challenges ([@DDP498C29],[@DDP498C30]) and one approach is by scoring enrichment from the Gene Ontology (GO) ([www.geneontology.org](www.geneontology.org)) by way of a χ^2^ test (see Materials and Methods). Accordingly, we calculated this for both differentially expressed genes and for aberrantly spliced genes. Enrichment analyses often can be difficult to interpret and *P*-values deceptively low and thus in order to understand our results, we also calculated enrichment in each of the 10 permuted data sets using a comparable number of genes. Analysis of differentially expressed genes in the motor neuron enriched mRNA pool did not reveal clearly definable biological enrichment above noise levels (Fig. [2](#DDP498F2){ref-type="fig"}C). But enrichment analysis of the aberrantly spliced gene cohort, in contrast, revealed robust enrichment above noise levels: we estimate a data-specific 5% noise level threshold of *P*≈10^−20^ and at this level of significance, there are 33 pathways in our true data and an average of 1.6 pathways (range 0--4) in our permuted data (Fig. [2](#DDP498F2){ref-type="fig"}D and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). Some gene sets have enrichment *P*-values \<10^−57^.

The specific enrichments that we identified in the motor neuron enriched mRNA pool are predominately related to cell adhesion and extracellular matrix (ECM) biology (Table [3](#DDP498TB3){ref-type="table"} and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). Transmembrane receptor protein tyrosine kinase activity, vascular endothelial growth factor receptor activity and regulation of cell motility were also identified (Table [3](#DDP498TB3){ref-type="table"} and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). While the 33 gene sets with *P* ≤ 10^−20^ contained a total number of 355 genes, many genes appeared redundantly in the gene sets and only 111 of these were unique. Of these, 57 specifically relate to cell adhesion and related functions (Fig. [3](#DDP498F3){ref-type="fig"}). In the sub-categories of cell adhesion, genes associated with cell--matrix adhesion and cell--substrate adhesion were far more abundant than those associated with cell--cell adhesion (enrichment *P* = 10^−31^ versus *P* = 10^−12^, respectively). When examining the 57 genes identified by cell adhesion, genes encoding transmembrane (*n* = 24) and secreted (*n* = 21) proteins were more highly represented than genes encoding nuclear (*n* = 2) or cytoplasmic (*n* = 10) proteins (Table [4](#DDP498TB4){ref-type="table"}). Most of these 57 genes (*n* = 52) were up-regulated and only a few (*n* = 5) were down-regulated, although the up- and down-regulation did not always meet statistical significance (Fig. [3](#DDP498F3){ref-type="fig"} and Table [4](#DDP498TB4){ref-type="table"}). A large number of genes were associated with integrin signaling, representing both ligands (collagens, laminins, fibronectin) and receptors.

![Heat map of the gene expression levels of the 57 cell adhesion genes identified by their aberrant splicing in the motor neuron enriched mRNA pool in our study. These 57 genes comprise the cell adhesion biological pathway as defined in the Gene Ontology. They were identified in our study by virtue of their marked over-representation in the 411 aberrantly spliced genes identified in the motor neuron enriched mRNA pool in SALS (*P* \< 10^−57^). The colored bar indicates the range of intensity values for each gene and the heat maps display their overall gene expression levels, not their aberrant splicing. Note the relatively clean separation of SALS and control groups and the preponderant up-regulation or over-expression of these genes, which is seen in addition to their aberrant splicing. (C, control and A, SALS).](ddp49803){#DDP498F3}

###### 

Biological enrichment of aberrantly spliced genes

  Enrichment                                                Enrichment *P*-value   \% genes in group that are present   Number of genes present   Number of genes in group   GO ID   GO category
  --------------------------------------------------------- ---------------------- ------------------------------------ ------------------------- -------------------------- ------- -------------
  Biological adhesion                                       10^−58^                8.6758                               57                        657                        22610   BP
  Cell adhesion                                             10^−58^                8.6758                               57                        657                        7155    BP
  Basement membrane                                         10^−48^                28.9474                              11                        38                         5604    CC
  Transmembrane receptor protein tyrosine kinase activity   10^−43^                20.5882                              14                        68                         4714    MF
  Collagen                                                  10^−43^                28.5714                              10                        35                         5581    CC
  Extracellular matrix structural constituent               10^−42^                18.75                                15                        80                         5201    MF
  Vascular endothelial growth factor receptor activity      10^−42^                50                                   6                         12                         5021    MF
  Laminin-1 complex                                         10^−41^                62.5                                 5                         8                          5606    CC
  Laminin complex                                           10^−41^                62.5                                 5                         8                          43256   CC
  Transmembrane receptor protein kinase activity            10^−41^                18.2927                              15                        82                         19199   MF
  Regulation of cell migration                              10^−39^                29.0323                              9                         31                         30334   BP
  Cell--substrate adhesion                                  10^−31^                17.3913                              12                        69                         31589   BP
  Cell--matrix adhesion                                     10^−28^                17.1875                              11                        64                         7160    BP
  Extracellular region part                                 10^−27^                6.38003                              46                        721                        44421   CC
  Protein binding                                           10^−27^                3.32847                              228                       6850                       5515    MF
  Plasma membrane part                                      10^−25^                4.74517                              81                        1707                       44459   CC
  Regulation of cell motility                               10^−25^                14.2857                              12                        84                         51270   BP
  Cell--substrate junction assembly                         10^−25^                60                                   3                         5                          7044    BP
  Cell junction assembly                                    10^−25^                60                                   3                         5                          34329   BP
  Extracellular matrix organization and biogenesis          10^−24^                19.5122                              8                         41                         30198   BP
  Collagen binding                                          10^−23^                29.4118                              5                         17                         5518    MF
  Phosphate transport                                       10^−23^                13.1868                              12                        91                         6817    BP
  Hemidesmosome                                             10^−23^                100                                  2                         2                          30056   CC
  Integrin-mediated signaling pathway                       10^−23^                16.3636                              9                         55                         7229    BP
  Proteinaceous extracellular matrix                        10^−22^                9.00901                              20                        222                        5578    CC
  Regulation of embryonic development                       10^−22^                50                                   3                         6                          45995   BP
  Stereocilium                                              10^−22^                50                                   3                         6                          32420   CC
  Fibroblast growth factor receptor activity                10^−22^                50                                   3                         6                          5007    MF
  Extracellular matrix                                      10^−21^                8.77193                              20                        228                        31012   CC
  Anatomical structure development                          10^−21^                5.15464                              55                        1067                       48856   BP
  Structural molecule activity                              10^−21^                5.91716                              40                        676                        5198    MF
  Integrin complex                                          10^−20^                21.4286                              6                         28                         8305    CC
  Developmental process                                     10^−20^                4.04485                              101                       2497                       32502   BP

BP, biological process; MF, molecular function; CC, cellular component.

###### 

Aberrantly spliced cell adhesion genes

  Gene symbol   Gene name                                                        RefSeq         Alt. splice *P*-value   Differential expression *P*-value   Fold change (A versus C)   Number of markers   Protein location
  ------------- ---------------------------------------------------------------- -------------- ----------------------- ----------------------------------- -------------------------- ------------------- ------------------
  AEBP1         AE binding protein 1                                             NM_001129      2.44E−10                0.0186655                           1.69315                    27                  sec
  ANXA9         Annexin A9                                                       NM_003568      8.62E−07                0.971328                            −1.00249                   14                  cyt
  CDH11         Cadherin 11, type 2, OB-cadherin (osteoblast)                    NM_001797      2.94E−06                0.00458728                          1.65623                    21                  tm
  CDH5          Cadherin 5, type 2, VE-cadherin (vascular epithelium)            NM_001795      2.36E−06                0.102509                            1.27449                    19                  tm
  CDH23         Cadherin-like 23                                                 NM_022124      1.61E−07                0.156179                            1.12818                    71                  tm
  CTNNA3        Catenin (cadherin-associated protein), alpha 3                   NM_013266      6.53E−06                0.00648134                          1.79781                    25                  cyt
  CTNND2        Catenin (cadherin-associated protein), delta 2                   NM_001332      1.59E−06                0.0867763                           1.1616                     32                  cyt
  CD44          CD44 molecule (Indian blood group)                               NM_000610      5.13E−12                0.000479249                         1.89535                    21                  tm
  CLDN10        Claudin 10                                                       NM_182848      6.03E−06                0.162268                            1.20723                    12                  tm
  CLDN11        Claudin 11 (oligodendrocyte transmembrane protein)               NM_005602      1.94E−06                0.00435624                          1.53442                    6                   tm
  COL3A1        Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type)        NM_000090      3.84E−09                0.221719                            1.17435                    49                  sec
  COL6A3        Collagen, type VI, alpha 3                                       NM_004369      3.34E−20                0.0945555                           1.36456                    45                  sec
  COL11A1       Collagen, type XI, alpha 1                                       NM_001854      2.33E−09                0.178053                            1.20705                    46                  sec
  COL12A1       Collagen, type XII, alpha 1                                      NM_004370      1.69E−10                0.0105983                           1.79078                    69                  sec
  COL13A1       Collagen, type XIII, alpha 1                                     NM_005203      6.71E−09                0.169929                            1.15626                    25                  sec
  COL14A1       Collagen, type XIV, alpha 1 (undulin)                            NM_021110      1.06E−08                0.00638787                          1.58704                    24                  sec
  COL27A1       Collagen, type XXVII, alpha 1                                    NM_032888      1.43E−06                0.243964                            −1.10262                   46                  sec
  CSF3R         Colony stimulating factor 3 receptor (granulocyte)               NM_156039      2.04E−06                0.126098                            1.10957                    24                  tm
  CYR61         Cysteine-rich, angiogenic inducer, 61                            NM_001554      1.17E−07                0.0315499                           1.55961                    8                   sec
  DDR1          Discoidin domain receptor family, member 1                       NM_013993      4.24E−08                0.103136                            1.15821                    31                  tm
  DST           Dystonin                                                         NM_183380      9.73E−24                0.323111                            1.0925                     125                 cyt
  ENG           Endoglin (Osler-Rendu-Weber syndrome 1)                          NM_000118      5.65E−06                0.342529                            1.19248                    20                  tm
  ERBB2IP       Erbb2 interacting protein                                        NM_018695      6.83E−07                0.000240051                         2.08535                    30                  cyt
  ECM2          Extracellular matrix protein 2, female organ and adipocyte       NM_001393      4.60E−06                0.0461937                           1.59777                    20                  sec
  FAT           FAT // FAT tumor suppressor homolog 1 (Drosophila)               NM_005245      1.45E−08                0.00159728                          1.86066                    31                  tm
  FN1           Fibronectin 1                                                    NM_212482      2.24E−21                0.0133788                           2.50828                    63                  sec
  HMCN1         Hemicentin 1                                                     NM_031935      7.81E−07                0.209353                            1.1854                     116                 sec
  HSPG2         Heparan sulfate proteoglycan 2                                   NM_005529      2.11E−09                0.938373                            −1.00658                   101                 sec
  HEPACAM       Hepatocyte cell adhesion molecule                                NM_152722      2.96E−06                0.0223096                           1.54885                    13                  tm
  IGSF11        Immunoglobulin superfamily, member 11                            NM_001015887   5.57E−08                0.0724414                           1.24835                    13                  tm
  ITGA6         Integrin, alpha 6                                                NM_000210      9.56E−08                0.0229754                           2.06743                    29                  tm
  ITGAX         Integrin, alpha X (complement component 3 receptor 4 subunit)    NM_000887      7.10E−08                0.305373                            1.09177                    29                  tm
  ITGB3         Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)      NM_000212      1.12E−06                0.394661                            1.16482                    20                  tm
  ITGB4         Integrin, beta 4                                                 NM_000213      4.07E−15                0.183707                            1.14822                    44                  tm
  ITGB7         integrin, beta 7                                                 NM_000889      1.28E−12                0.345837                            −1.07065                   17                  tm
  ITGBL1        ITGBL1 // integrin, beta-like 1 (with EGF-like repeat domains)   NM_004791      2.24E−14                0.00392462                          1.97861                    16                  tm
  JAM2          Junctional adhesion molecule 2                                   NM_021219      3.87E−08                0.00548407                          2.02731                    13                  tm
  LAMB1         Laminin, beta 1                                                  NM_002291      2.61E−13                0.0290629                           1.61794                    36                  sec
  LAMB2         Laminin, beta 2 (laminin S)                                      NM_002292      3.16E−06                0.155571                            1.21405                    40                  sec
  LAMC3         Laminin, gamma 3                                                 NM_006059      8.59E−06                0.370666                            −1.06083                   35                  sec
  LPP           LIM domain containing preferred translocation partner in lip     NM_005578      1.40E−06                0.147014                            1.51955                    13                  cyt
  MYBPC1        Myosin binding protein C, slow type                              NM_002465      1.90E−21                0.00967833                          1.31138                    31                  cyt
  NCAN          Neurocan                                                         NM_004386      4.77E−10                0.206516                            1.13639                    25                  sec
  NRP2          Neuropilin 2                                                     NM_003872      5.65E−07                0.0447044                           1.29315                    36                  tm
  PARVG         Parvin, gamma                                                    NM_022141      2.03E−07                0.015984                            1.25824                    14                  cyt
  PDZD2         PDZ domain containing 2                                          NM_178140      2.86E−07                0.0529539                           1.34362                    44                  cyt
  PECAM1        Platelet/endothelial cell adhesion molecule (CD31 antigen)       NM_000442      3.50E−06                0.023662                            2.42764                    17                  tm
  PCDHGC5       Protocadherin gamma subfamily C, 5                               NM_018929      2.24E−21                0.00182203                          1.23154                    100                 tm
  RELN          Reelin                                                           NM_173054      3.03E−06                0.0459772                           1.59369                    73                  sec
  SSPN          Sarcospan (Kras oncogene-associated gene)                        NM_005086      1.23E−07                0.00153469                          1.87677                    8                   tm
  SEMA5A        Sema domain, seven thrombospondin Repeats                        NM_003966      6.24E−06                0.132723                            1.27857                    29                  tm
  SOX9          SRY (sex determining region Y)-box 9 (campomelic dysplasia)      NM_000346      3.07E−07                0.584737                            1.05446                    9                   nuc
  TNC           Tenascin C (hexabrachion)                                        NM_002160      2.55E−08                0.125224                            1.66206                    36                  sec
  TESK2         Testis-specific kinase 2                                         NM_007170      6.75E−07                0.0632463                           1.36536                    14                  nuc
  TRIP6         Thyroid hormone receptor interactor 6                            NM_003302      2.74E−07                0.194651                            1.16145                    13                  cyt
  VCAN          Versican                                                         NM_004385      8.36E−11                0.000148832                         2.61415                    26                  sec
  VWF           von Willebrand factor                                            NM_000552      5.40E−12                0.085195                            1.51082                    46                  sec

cyt, cytoplasmic; nuc, nuclear; sec, secreted; tm, transmembrane.

There are no clearly identifiable gene signals in the anterior horn enriched mRNA pool {#s2f}
--------------------------------------------------------------------------------------

As previously stated, involvement of the microenvironment ('non-neuronal neighbors') is an important aspect of ALS pathobiology in transgenic mice expressing mutant SOD1 ([@DDP498C3]) and thus to study it in SALS, we collected and profiled the entire anterior horn after removal of motor neurons. We had comparable quality of data as the motor neuron enriched mRNA pool ([Supplementary Material S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)) but when applying the same bioinformatics analyses that we used for the motor neuron enriched pool, we could not identify any mRNA gene signals above noise levels either by way of differential gene expression, aberrant splicing, or biological enrichment ([Supplementary Material S3](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)), thus demonstrating the compartment-specific nature of our findings. To better understand this lack of signal in the anterior horn, we examined our analogous G93A mouse data that used 3′ gene expression arrays and determined signal strength in the anterior horn and in motor neuron enriched mRNA pools isolated by microdissection using a similar bioinformatics analysis. At both 20 and 60 post-natal days, we identified significant and comparable numbers of differentially expressed genes above experiment-specific noise levels in both pools (data not shown), thus demonstrating different strengths of genomic expression in the relevant histological compartments between mouse SOD1 and human SALS samples.

The biological enrichments of aberrant exon splicing in SALS and in an SMA mouse model of motor neuron degeneration are highly concordant {#s2g}
-----------------------------------------------------------------------------------------------------------------------------------------

Recently, exon splicing in a mouse model of SMA motor neuron degeneration using whole genome exon arrays demonstrated widespread tissue-specific aberrant splicing, supporting the hypothesis that functional loss of the SMN1 protein in spliceosomes and aberrant splicing are fundamental in disease pathogenesis ([@DDP498C24]). To compare our findings to those in this study in uniform manner, we downloaded the CEL files of the spinal cord tissues from this study and processed them the same way we processed our own. With the bioinformatics approach reported in the study, 259 genes were identified as being aberrantly spliced in the spinal cord. Using our bioinformatics approach estimating data-specific noise thresholds, 74 genes were identified (data not shown). By either approach, there was significant aberrant splicing in degenerating tissues. There was a greater degree of aberrant splicing in our human SALS tissues (*n* = 411) than in the SMA mouse model tissues (*n* = 74), a difference likely due to greater compartment specificity in our study using microdissection. While this supports emerging ideas about a role of exon splicing in motor neuron diseases, in fact the ability to detect global splicing alterations is relatively recent with the development of exon arrays and few studies have been reported. To better understand this, we next compared the SALS and SMA data with others recently reported in the literature in non-motor neuron disease conditions ([@DDP498C31],[@DDP498C32]). We downloaded CEL files from these studies and processed them the same way we processed our own data. We found even greater degrees of aberrant gene splicing occurring in these other conditions (data not shown), thus reinforcing that important biologic functions relate to exon splicing.

This functional specificity of exon splicing is clearly supported by enrichment analyses. The SMA mouse model study also identified enrichment of ECM biology in the cohort of aberrantly spliced genes, although quantitative analysis was not presented and the finding was not emphasized. To compare our findings to the ones reported in this study in uniform manner, we sought enrichment the same way we sought it in ours and we noted comparably robust enrichment: in the SMA study, we identified 26 gene sets with enrichment *P* ≤ 10^−20^, the cutoff we calculated for their noise. Some gene sets had enrichment *P*-values \<10^−78^. The specific enrichments were dominantly related to ECM, collagen, cell adhesion, and related functions ([Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). While the 26 gene sets with enrichment *P* ≤ 10^−20^ contained a total number of 185 genes, many genes appeared redundantly in the gene sets and only 48 were unique. Of these, 32 specifically relate to ECM, cell adhesion, and related functions. Of the 48 unique genes from the SMA study and the 111 unique genes from our SALS study identified by the respective enrichment analyses, only 5 overlapped (col12a1, col14a1, fn1, hspg2 and itgb4) ([Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)).

TARDBP/TDP-43, TDP-43 targets and other genes of ALS interest are mostly normal {#s2h}
-------------------------------------------------------------------------------

We interrogated our data for currently known genes of interest in SALS pathobiology. A 1.5-fold change of TARDBP has been previously reported in brains of frontotemporal lobar dementia with ubiquitinated pathology using microarray analysis, although the replicates were small and tissue was not cell-specific ([@DDP498C33]). In our array data, we also found that this might be true in the motor neuron enriched mRNA pool (1.3-fold change with *P* = 0.008) but not the anterior horn enriched mRNA pool, but subsequent qPCR of all 12 SALS and 10 controls samples did not validate this (data not shown). TARDBP was normally spliced and we therefore conclude TARDBP mRNA transcription is normal in SALS. We also interrogated our data for known targets of TDP-43---CFTR, APO A-II, and CDK6---and we found they were neither differentially expressed nor aberrantly spliced. The representations for SMN1 and SMN2 are sparse on the array and what little could be assayed did not demonstrate differential gene expression (aberrant splicing could not be determined). We also interrogated our data for currently known genes of interest in FALS and motor neuron disease biology other than TARDBP---SOD1, FUS/TLS, SETX, ATXN7, IGHMBP2, ELP3 and ANG---and they were neither differentially expressed nor aberrantly spliced. As the targets of these genes are largely unknown, we cannot comment further on their possible aberrant splicing. Glycyl-tRNA synthetase (GARS), which is of putative interest in ALS ([@DDP498C22]), appeared to demonstrate significant down-regulation (−1.4-fold change with *P* = 0.0006) by microarray but this was not validated by subsequent qPCR (data not shown). In addition, we looked at genes identified by the Gene Ontology as involved in RNA processing and identified 39 genes as being either aberrantly spliced or differentially expressed, although this biological category was not abnormally enriched by enrichment analysis. We also found that the glutamate transporter EAAT2 (SLC1A2), which is potentially aberrantly spliced in ALS ([@DDP498C34]) was not abnormal, consistent with another report ([@DDP498C35]); however, we did observe that two other glutamate transporters, EAAT1 (SLC1A3) and EAAT4 (SLC1A6) might be differentially expressed (2.5-fold change with *P* = 0.0001 and −1.2-fold change with *P* = 0.007, respectively) and both validated by qPCR (*P* = 0.025) ([Supplementary Material, S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)).

qPCR validates microarray predictions of aberrantly spliced gene candidates {#s2i}
---------------------------------------------------------------------------

In order to validate aberrant exon splicing between the SALS and control as predicted by the exon arrays, 12 candidate genes were selected and exons within these genes predicted to exhibit differences and lack of difference were both assayed by TaqMan qPCR (see Materials and Methods). These genes were chosen from a variety of biological pathways to assay for splicing differences in various biological processes ([Supplementary Material S4](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). Eight out of the 12 genes or 67% (EDNRB, PAX6, SF1, TMBIM1, TRBV19, VCAN, ARHGAP15 and AQP4) as illustrated in Figure [4](#DDP498F4){ref-type="fig"} showed both of the changes predicted by the exon array in the same gene ([Supplementary Material S4](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)). This level of PCR validation is consistent with or above those in similar exon array studies ([@DDP498C36]--[@DDP498C38]) and we are thus reassured of the validity of the exon array predictions.

![Aberrant splicing predictions of the exon arrays validate by qPCR. Four examples of validation of aberrant splicing are demonstrated in this figure. The gene views on the left show the expression of exons as determined by exon array; the expression levels are shown on a log~2~ scale; the error bars show standard errors of means; SALS, red triangles; control, blue squares. Exons showing similar (**A**) and different (**B**) expression between SALS and control (arrows) were selected for validation by qPCR. The bar plots on the right show the results of qPCR: expression of the selected exons are normalized to GAPDH and shown on a log~2~ scale; the error bars show the 95% conﬁdence intervals; SALS, red; control, blue. Asterisks indicate signiﬁcant difference by *t*-test (α = 0.05) in expression as predicted by the microarray. In these examples, exons predicted to have differential expression and exons predicted not to have differential expression were confirmed by qPCR.](ddp49804){#DDP498F4}

DISCUSSION {#s3}
==========

We made three key observations, the foundation of which is summarized in Table [5](#DDP498TB5){ref-type="table"}. The first key observation is that genomic abnormalities in SALS are highly localized to the motor neuron enriched mRNA pool (the degenerating anatomic compartment) and not apparent in the anterior horn enriched mRNA pool (the surrounding microenvironment). The strength of signal in the former and the lack of signal in the latter (which is itself enriched by removal of nearly 75% of the surrounding spinal cord) show this and the critical importance of anatomic and technical precision in identifying pathologic changes *in vivo*. The exact identity of the motor neuron enriched mRNA pool is not entirely clear. In favor of its mRNA deriving mostly from motor neurons is the anatomic specificity of microdissection and our preliminary histological studies of these same tissues in FFPE that do not show obvious surrounding hypercellularity. In favor of its containing mRNA also from non-motor cells is the difficulty of resolving cell morphology in the frozen cryosections on which microdissection is performed, the identification of biological enrichment that may be external to the cell itself (cell--adhesion, cell--matrix and ECM), and the identification of a number of genes that appear to be primarily glial. Thus, while enriched in microdissected motor neurons, it is possible that the mRNA signals are also enriched in other proximate cells or their mRNA-rich processes.

###### 

Summary of key findings

                                                            Motor neuron enriched mRNA pool                                                                                                                                                                               Anterior horn enriched mRNA pool
  --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  Cellularity                                               Homogeneous (single-cell enriched)                                                                                                                                                                            Heterogeneous (glia, endothelium, small neurons, degenerating neurons)
  Anatomic size                                             Highly discrete                                                                                                                                                                                               Comparatively vast
  Differential gene expression                              148 genes                                                                                                                                                                                                     Not detectable above noise
  Biological enrichment of differentially expressed genes   Not detectable above noise                                                                                                                                                                                    Not detectable above noise
  Aberrant exon splicing                                    411 genes                                                                                                                                                                                                     Not detectable above noise
  Biological enrichment of aberrantly spliced genes         Cell--matrix adhesion and extracellular matrix biology; also transmembrane receptor protein tyrosine kinase activity, vascular endothelial growth factor receptor activity, and regulation of cell motility   Not detectable above noise

A striking finding is lack of signal and biologic enrichment in the anterior horn enriched mRNA pool. While this lack of signal validates our strategic approach of separating the two compartments, it is surprising given the strong evidence indicating that motor neuron degeneration is non-autonomous in mice expressing mutant SOD1 ([@DDP498C3],[@DDP498C4]) and the strong evidence supporting the role of glia in magnifying the motor neuron pathology associated with ALS ([@DDP498C39]--[@DDP498C41]). In our comparable data from mutant SOD1 transgenic mice, we did in fact show equal signal strengths between the motor neuron and the anterior horn enriched mRNA pools. There are a number of potential explanations for this difference in human disease and the mutant SOD1 transgenic mouse model. In humans, the anterior horn is much larger anatomically than in mice and the critical interactions may reside in very close apposition to the neurons and thus detectable in the motor neuron enriched mRNA pool but diluted in the anterior horn enriched mRNA pool. In humans, the larger-sized anterior horn compared with mice may allow greater cellular heterogeneity and greater noise. In humans, the changes are sequential and summating, whereas in mice they are temporally synchronized. In humans, the effects in the anterior horn may be subtler than in mice and not detectable with our bioinformatics-based approach. Or, of course, non-autonomous cell effects may not be as significant in SALS pathognesis as in the SOD1 mouse model, upon which most of the non-autonomous cell degeneration literature is based.

The second key observation of our study is that exon splicing is more significant and relevant than differential gene expression in SALS---signals are more clearly identified and their biological enrichment more robustly defined by profiling aberrant exon splicing than differential gene expression. This supports the critical biological ([@DDP498C6]--[@DDP498C8]) and pathologic ([@DDP498C10]) importance of exon splicing in general and its interest to ALS ([@DDP498C14]--[@DDP498C24]) in particular. TDP-43 is the leading candidate in SALS pathogenesis and its exact role in pathogenesis is fundamental but remains unclear ([@DDP498C14]). Since one of its main known functions is exon splicing and in SALS it mislocalizes from the nucleus to the cytoplasm, it is important to note that we could not detect expression or splicing changes in its encoding gene TARDBP or any of its known targets including CFTR, APO A-II, CDK6 and SMN1. Together, these suggest that its role in SALS pathobiology is not likely at its own mRNA level and that it likely involves some other yet-to-be-identified targets or mechanisms---to date, a comprehensive list of TDP-43 targets and actions has not been defined. Alternatively, TDP-43 may involve functions other than exon splicing and the importance of the aberrant splicing that was detected by us is separate. The important role exon splicing may play in motor neuron degeneration is highlighted by SMA ([@DDP498C42]). SMA is caused by homozygous loss of the SMN gene, which is essential for biogenesis of small nuclear ribonucleoprotein particles that are critical components of the RNA splicing apparatus ([@DDP498C43]). Thus, splicing abnormalities are expected to play major roles in motor neuron degeneration and have been demonstrated in a mouse model to be both widespread and tissue-specific, differing within different neuronal tissues and between neuronal and non-neuronal tissues ([@DDP498C24]). Together with our study, splicing abnormalities are shown to be cell-specific as well as tissue-specific.

The mechanistic bases of the aberrant splicing in ALS are unclear. A number of RNA processing factors are themselves aberrantly spliced or differentially expressed in our SALS samples ([Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)), which may provide an explanation for at least part of the splicing changes in SALS. We do not know if the genes encoding these RNA processing factors are mutated in SALS, similar to FUS/TLS or TDP-43, or if they are abnormally regulated downstream of primary disease-causing genes, but they represent interesting candidates for further analysis. For example, SF1 and SFRS2 have been shown to associate with FUS/TLS ([@DDP498C44],[@DDP498C45]) and SFRS2 also alters the splicing of the TDP-43 target APO A-II ([@DDP498C46]), while SFRS5 alters the splicing of two TDP-43 targets (APO A-II and CFTR) ([@DDP498C46],[@DDP498C47]). In addition, ELAVL3 (HuC) has a role in paraneoplastic neurologic disorders ([@DDP498C48]) and neuronal development ([@DDP498C49]). Interestingly, mutant SOD1 competes with HuC (and HuR) for binding to the 3′-UTR of vascular endothelial growth factor (VEGF) ([@DDP498C50]). RNASET2 is of interest due to the potential role of angiogenin (also an RNase) in ALS ([@DDP498C22]), as well as the recently demonstrated effects of RNASET2 loss on neuronal development ([@DDP498C51]). PTPBP1 represents a key regulator of neuronal development through its effects on repressing neural PTP (also called PTBP2) ([@DDP498C52]), as loss of PTPBP1 results in neural differentiation associated with PTPBP2 activation ([@DDP498C53]). There is also recent evidence of PTPBP1 involvement in the proliferation and migration of gliomas ([@DDP498C54]).

The third key observation of our study is the specific identification in SALS of perturbation of cell adhesion and ECM biology, especially cell--matrix as opposed to cell--cell adhesion genes. Other identified pathways included transmembrane receptor protein tyrosine kinase activity, vascular endothelial growth factor receptor activity \[already of great interest in ALS pathobiology ([@DDP498C55])\] and regulation of cell motility (Tables [3](#DDP498TB3){ref-type="table"} and [5](#DDP498TB5){ref-type="table"}). Since these were only identified in the motor neuron enriched mRNA pool and not in the larger surroundings of the anterior horn, their gene action is at or very proximate to neurons. Most of the cell adhesion genes we identified encode proteins that are either secreted or transmembrane as opposed to cytosolic or nuclear. The mechanisms by which these genes are likely to exert their effects are on the structure of the encoded proteins because the key to their identification was the aberrant splicing of the exons in the genes encoding them. Their abnormal action is likely to be part of an active rather than passive process since they are also mostly over-expressed or up-regulated. Where in the cascade of motor neuron degeneration their perturbations occurs or whether their perturbations are primary or secondary are unknown---their identification depended on pooling motor neurons within each nervous system and analysis of signals among multiple nervous systems. But the perturbations arguably are relatively upstream: (i) studies were performed in regions to which the degenerative process was newly advancing and therefore neuron-rich (in fact, these studies are only feasible in such regions) ([@DDP498C26]); (ii) the neurons in these regions showed relatively inconspicuous changes histologically when examined in companion FFPE tissues; and (iii) microdissection has an intrinsic bias for selectively collecting larger and healthier motor neurons. The studies on the mouse model of SMA highlight the functional and biological importance of the specific perturbations of cell--matrix and ECM biology: what is most concordant between SALS and SMA motor neuron degeneration is not aberrant exon splicing *per se*---there are only five genes that overlap---but the nearly identical and highly robust biological enrichments of the two distinct aberrant spliced gene cohorts. The source and coordination of the aberrant splicing is unknown and would only be identified by our method if altered in either expression or splicing. While we did observe alterations of RNA processing factors (mentioned above and [Supplementary Material S2](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1)), there are many other possible alterations such as point mutations or post-translational changes that we are not able to observe. It is even possible, as demonstrated by SMA, that alterations in only one factor could cause multiple splicing abnormalities, but for the same reasons we might not be able to detect such.

Motor neurons are surrounded by a rich structural as well as cellular matrix and there are a number of potential scenarios where altered cell--matrix interactions could significantly affect neuron function. Disruption of cell--matrix molecules could adversely affect glia as well as neurons, thus resulting in or resulting from dysfunction of both cell categories ([@DDP498C56]). A few possibilities are outlined. (i) Alterations in the ECM could aberrantly modify the diffusion kinetics of paracrine factors such as growth factors, purines, etc., resulting in too much or too few of these factors reaching adjacent cells ([@DDP498C57]). (ii) Alterations in ECM could adversely affect neurons via integrin adhesion and signaling ([@DDP498C58]). (iii) Cell--matrix interactions are critical for neuronal migration, which occurs primarily during development as neural progenitor cells migrate to their proper positions before differentiating ([@DDP498C59]). Abnormal cell--matrix interactions could alter the normal formation and wiring of the nervous system, thus priming a delayed failure ([@DDP498C60]). (iv) Alterations in the ECM might cause or reflect derangements to the release of or diffusion of chemoattractants that activate neural progenitor cells and promote their migration toward diseased structures to try to 'rescue' degenerating motor neurons ([@DDP498C61]); alterations in the ECM might allow propagation of a maladapted process. (v) The basal lamina in the CNS, which is comprised predominately of ECM proteins, serves an important role in modulating the permeability of the blood brain barrier ([@DDP498C62]). Cleavage of proteins in the basal lamina by matrix metalloproteinases produced by invading inflammatory cells is required to facilitate their access to the CNS ([@DDP498C63]), thus alterations in ECM protein isoforms could alter blood brain barrier permeability. In addition, we have found that a protein crucial for determining the water permeability of the blood brain barrier, aquaporin-4 ([@DDP498C62]), demonstrates increased expression of a specific isoform in SALS (see Results). Overexpression of aquaporin-4 has been reported in ALS mouse ([@DDP498C64]) and rat models ([@DDP498C65]). It is interesting to note evidence from mouse ALS models indicating blood brain barrier changes early in the disease process ([@DDP498C66]). And (vi), ECM proteins can directly affect cells or alter the interactions of other ECM proteins with adjacent cells. For example, the ECM protein versican, which demonstrates altered splicing in SALS (see Results), is thought to restrict neuronal plasticity in adults as a component of perineuronal nets ([@DDP498C67],[@DDP498C68]) and is upregulated in a rat model of ALS ([@DDP498C66]). Additionally, versican promotes the assembly of hyaluronan ([@DDP498C69]), which can activate microglia though binding to the CD44 receptor ([@DDP498C70]) (which also undergoes altered splicing in SALS).

These three key observations of our study are especially interesting in light of our recent postulations that motor neuron degeneration in SALS is an actively spreading and propagating process ([@DDP498C71]). That the aberrantly spliced genes are up-regulated is consistent with the process being active rather than passive. That the aberrantly spliced genes have perturbed cell--matrix and ECM adhesion biology is consistent with the importance of interactions in the microenvironment that could advance in space and over time. In this regard, it is important to note that there are two general types of inter-neuronal communication: one is synaptic communication between neurons that are in series (such as between upper and lower motor neurons or between neurons and interneurons) and the other is local side-to-side communication between neurons that are in parallel and involves local paracrine signaling and the neuron microenvironment. The recent identification that one or more soluble factors are selectively toxic to motor neurons is especially intriguing ([@DDP498C72]). One of many scenarios that can be imagined is that perturbed cell adhesion induces local changes and release of toxic soluble factors recruiting nearby cells, thus propagating a non-accelerating pathologic process. In the final analysis, our findings do not distinguish primary from secondary changes in pathobiology and add more pieces to the complex puzzle. Many challenges and questions remain, an immediate one being biological validation of our largely bioinformatics-based findings.

MATERIALS AND METHODS {#s4}
=====================

Tissue acquisition and repository {#s4a}
---------------------------------

All nervous systems were acquired by way of an Investigational Review Board and Health Insurance Portability and Accountability Act compliant process. The SALS nervous systems were from patients who had been followed during the clinical course of their illness and met El Escorial criteria for definite ALS ([@DDP498C73]). Upon death, autopsies were performed immediately by an on-call tissue acquisition team. Control nervous systems were from patients from the hospital\'s critical care unit when life support was withdrawn ([@DDP498C7]), patient on hospice ([@DDP498C1]) and from the Pennsylvania Tissue Repository ([@DDP498C2]). Tissue collections were completed within 6 h, usually within 4 h, of death and the entire motor system was dissected and elaborately archived for downstream applications by creating two parallel tissue sets from alternating adjacent regions. For molecular studies, segments were embedded in cutting media, frozen on blocks of dry ice and stored at −80°C. For structural studies, the adjacent segments were fixed in 70% neutral buffered formalin, embedded in paraffin (formalin-fixed paraffin-embedded or FFPE) and stored at room temperature.

Microdissection and total RNA isolation {#s4b}
---------------------------------------

Thirty to forty 8--10 µm cryocut frozen tissue sections stained with cresyl violet acetate were microdissected from each nervous system on a Pixcell IIe Laser Capture Microdissection (LCM) System (Arcturus Bioscience) in a 2-h long epoch for the motor neuron enriched RNA pool. Microdissected cells were captured on CapSure™ Macro LCM Caps (Arcturus Bioscience). After completion of LCM, the surrounding remaining anterior horn region was collected to create a second parallel RNA pool. RNA isolations were based on a guanadinium isothiocyanate and 2-mercaptoethanol extraction and column purification with RNeasy® Micro Kit (Qiagen).

mRNA amplification and exon array hybridization {#s4c}
-----------------------------------------------

For exon profiling, total RNA was amplified to cDNA probe using random priming with WT-Ovation™ Pico RNA Amplification System (NuGEN). The antisense--sense orientation was converted to sense transcript-cDNA (ST-cDNA) using WT-Ovation™ Exon Module (NuGEN). ST-cDNA was fragmented and biotin labeled using FL-Ovation™ cDNA Biotin Module v2 (NuGEN). Probe was hybridized to GeneChip® Human Exon 1.0 ST Arrays (Affymetrix). This array determines both exon and gene expression and are more resilient to RNA degradation changes than traditional 3′ gene arrays, which depend solely on integrity of the 3′ exon ([@DDP498C74]). Hybridized chips were stained and washed on a GeneChip 450 fluidics Station (Affymetrix) and scanned with a GeneChip 3000 scanner (Affymetrix). Initial data was processed to CEL files using GCOS Version 1.4 (Affymetrix). The microarray data presented herein and deposited in the GEO is MIAME compliant.

Quality control {#s4d}
---------------

RNA quality were assessed using digital microelectrophoresis with either a PicoChip™ or NanoChip™ (Agilent), which generated electropherograms, digital gels, and RNA Integrity numbers (RINs) ([@DDP498C75]). RNA quality was ascertained at each stage of processing---acquisition, microdissection, amplification, fragmentation---and studies were advanced only if optimal. Microarray quality was assessed by visualization of the microarray CEL files, percent positive calls on the microarray, area under the curve (AUC) values, distribution histograms of non-normalized expression scores, box plots of mean and 25th and 75th percentiles probe scores before and after quantile normalization, median normalized non-background corrected scores of probes designated as background, graphs of mean absolute difference between transformed background-corrected and normalized probe scores and frequency histograms of GC counts ([@DDP498C76]).

Bioinformatics {#s4e}
--------------

Primary bioinformatics analysis used Genomics Suite Version 6.4 (Partek). CEL files were imported into the software and their backgrounds underwent RMA and quantile normalizations. Statistical analysis was performed by creating from the individual CEL files two groups, control or SALS, and then comparing them to each other. The exon arrays have three types of probe sets: core, extended and full. The *core probe set* contains ∼17 800 transcript clusters and ∼284 000 probe sets to RefSeq and GenBank full-length mRNA\'s; the *extended probe set* contains ∼129 000 transcript clusters and ∼523 000 probe sets (plus core probes), with additional probes to expressed sequence tags (EST\'s) and partially annotated mRNA\'s; and the *full probe set* contains ∼262 000 transcript clusters and ∼580 000 probe sets (plus core and extended probes) with additional probes to all predicted exons in the genome. For our analysis, we have used the core probe set because of the depth of annotation available. The software uses a proprietary Exon Splice ANOVA algorithm to calculate both each gene\'s differential expression, which is determined by a composite expression of all its exons comparing between disease and control, and each gene\'s exon splice index, which is determined by exon-to-exon comparison between disease and control after correcting for other variables, including overall differential gene expression. Among the factors measured by the ANOVA are batch effects. Signal strengths and noise levels were measured in two ways. First, noise levels specific to our data were estimated by randomly permuting CEL file classifications to create comparisons between sham groups; 10 permutations were performed. Second, multiple test correction was performed by Bonferroni method; these data are reported in the [Supplementary Material](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1). Enrichment analysis was determined by generating an enrichment score equal to the *P*-value of a χ^2^ test comparing identified genes and their biological functionality as defined by Gene Ontology ([www.geneontology.org](www.geneontology.org)). Heat maps were generated by first summarizing the exons of each gene using the 'gene summary' command, followed by the 'cluster based on significant genes' command. Additional bioinformatics analysis was performed using Expression Console™ Version 1.1 (Affymetrix) and XRAY Version 3.92 (Biotique Systems).

Validation of array results by qPCR {#s4f}
-----------------------------------

Genes identified as being aberrantly spliced were selected for validation by qPCR. Exons exhibiting significant differences as well as lack of differences of expression between SALS and control were analyzed. Target sequences to these exons were obtained from Affymetrix. To these, primers and probes were designed using Applied Biosystem\'s Primer Express software program (Applied Biosystems Inc.). In the case of TDP-43, GARS, EAAT1 (SLC1A3), EAAT4 (SLC1A6) and GAPDH, standard TaqMan® probes were used (Applied Biosystems, Inc). qPCR was performed using either a 7900HT Fast Real Time PCR System or a 7500 Real Time PCR system using either a 384 or 96-well format (Applied Biosystems, Inc). Four-fold standard dilution curves were generated on each plate for each probe in an RT step using RNeasy-purified HEK 293 RNA (Qiagen). Test samples consisted of amplified cDNA from the motor neuron enriched RNA pools and were run in triplicate. The resulting data were normalized to endogenous GAPDH run in parallel on each plate. Values from 3--12 SALS and 3--10 control were separately determined, averaged between groups, and compared by two-tailed Welch\'s *t*-test using logarithmic scaling. We called a gene valid only if two conditions were both met: an exon predicted to have differential expression and an exon predicted not to have differential expression were confirmed by qPCR.

SUPPLEMENTARY MATERIAL {#s5}
======================

[Supplementary Material is available at *HMG* online](http://hmg.oxfordjournals.org/cgi/content/full/ddp498/DC1).
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